Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline.

[citation needed] Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.

Blocking this transporter causes blood glucose to be eliminated through the urine.

The remaining structure, which is the active substance, is called sergliflozin.

This drug article relating to the gastrointestinal system is a stub.